French Guiana Tech World
SEE OTHER BRANDS

Your science and technology news reporter from French Guiana

French Guiana Tech World: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Tech World.

Press releases published on July 24, 2025

Crusoe and Tallgrass Announce AI Data Center in Wyoming

Crusoe and Tallgrass Announce AI Data Center in Wyoming

DENVER, July 24, 2025 (GLOBE NEWSWIRE) -- Crusoe, the industry’s first vertically integrated AI infrastructure provider, today announced a strategic partnership with Tallgrass to develop a 1.8 gigawatt (GW) AI data center campus located in southeast …

Bel Reports Second Quarter and First Half 2025 Results

Bel Reports Second Quarter and First Half 2025 Results

WEST ORANGE, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Bel Fuse Inc. (Nasdaq: BELFA and BELFB) today announced preliminary financial results for the second quarter and first half of 2025. Second Quarter 2025 Highlights Net sales of $168.3 million compared to …

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated …

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the …

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body …

Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025

Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with …

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, …

Definitive Healthcare Announces Timing of Its Second Quarter 2025 Financial Results Conference Call and Webcast

Definitive Healthcare Announces Timing of Its Second Quarter 2025 Financial Results Conference Call and Webcast

FRAMINGHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its second quarter …

Teads to Release Second Quarter 2025 Financial Results on August 7, 2025

Teads to Release Second Quarter 2025 Financial Results on August 7, 2025

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Teads Holding Co. (NASDAQ: TEAD), announced today that the company will release its second quarter 2025 results before the market opens on Thursday, August 7, 2025, followed by a conference call at 8:30 a.m. ( …

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

LONDON, July 24, 2025 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 …

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the first patient has been dosed in VIKTORIA-2, its Phase 3 …

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

- Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Panel Meeting Scheduled on August 14, 2025 - SOUTH SAN …

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

REDWOOD CITY, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer- …

Brag House Announces $15 Million Private Placement

Brag House Announces $15 Million Private Placement

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Brag House Holdings, Inc. (NASDAQ: TBH) (“Brag House” or the “Company”) the Gen Z engagement platform operating at the intersection of gaming, college sports, and digital media, announces today that it has …

 Sunwave Health Achieves ONC Health IT Certification, Strengthening Its Commitment to Behavioral Health Providers

Sunwave Health Achieves ONC Health IT Certification, Strengthening Its Commitment to Behavioral Health Providers

DELRAY BEACH, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Sunwave Health, a leading provider of healthcare software solutions, today announced that its all-in-one platform has earned the prestigious ONC Health IT Certification from the Office of the National …

Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit

Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit

RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most …

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 …

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées

Cabometyx® est le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines non résécables ou métastatiques précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’ …

Mark Cuban Foundation Launches 2025 AI Bootcamps

Mark Cuban Foundation Launches 2025 AI Bootcamps

DALLAS, July 24, 2025 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation today announced significant updates and a nationwide expansion of its free AI Bootcamps, designed to bring advanced artificial intelligence education to underserved high school students …

Soulbound.TV Announces $SBX Token Launch on MEXC: July 25 at 12PM UTC

Soulbound.TV Announces $SBX Token Launch on MEXC: July 25 at 12PM UTC

New York, New York, July 24, 2025 (GLOBE NEWSWIRE) -- To support the launch, Soulbound.TV will also go live on CoinTerminal this Thursday, giving the public full transparency into tokenomics, performance data, and real-time market activity. What Is $SBX? $ …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions